POSB125 The Impact of Discounting on the Cost Effectiveness of Tisagenlecleucel for Relapsed/Refractory Acute Lymphoblastic Leukaemia
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.398
https://www.valueinhealthjournal.com/article/S1098-3015(21)02193-8/fulltext
Section Title :
Section Order :
11175
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02193-8&doi=10.1016/j.jval.2021.11.398